These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6415857)

  • 1. Mechanisms of action of sulphinpyrazone.
    Wallis RB
    Thromb Res Suppl; 1983; 4():31-8. PubMed ID: 6415857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of human platelet cyclo-oxygenase activity by sulfinpyrazone and three of its metabolites.
    Del Maschio A; Livio M; Cerletti C; De Gaetano G
    Eur J Pharmacol; 1984 Jun; 101(3-4):209-14. PubMed ID: 6432556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential inhibition of platelet thromboxane and lung prostacyclin production by sulphinpyrazone, acetylsalicylic acid and indomethacin by human tissues in vitro.
    Toivanen J; Ylikorkala O; Viinikka L
    Thromb Res; 1985 Feb; 37(4):493-502. PubMed ID: 3920778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of prolonged treatment with sulphinpyrazone on thromboxane A2 and prostacyclin in man.
    Viinikka L; Toivanen J; Ylikorkala O
    Br J Clin Pharmacol; 1982 Sep; 14(3):456-8. PubMed ID: 6812610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of sulphinpyrazone and its metabolites on platelet function in vitro and ex vivo.
    Pay GF; Wallis RB; Zelaschi D
    Haemostasis; 1981; 10(3):165-75. PubMed ID: 7262645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulphinpyrazone prevents in vivo the inhibitory effect of aspirin on rat platelet cyclo-oxygenase activity.
    Rajtar G; Cerletti C; Livio M; de Gaetano G
    Biochem Pharmacol; 1981 Oct; 30(20):2773-6. PubMed ID: 6797431
    [No Abstract]   [Full Text] [Related]  

  • 7. Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing.
    Pedersen AK; FitzGerald GA
    Clin Pharmacol Ther; 1985 Jan; 37(1):36-42. PubMed ID: 3917387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostaglandin endoperoxides and thromboxane A2 in thrombus formation in the hamster cheek pouch in vivo.
    Lewis GP; Smith JR
    Prostaglandins; 1984 Jul; 28(1):29-41. PubMed ID: 6435186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition by sulphinpyrazone of the platelet-dependent bronchoconstriction due to platelet-activating factor (PAF-acether) in the guinea pig.
    Chignard M; Wal F; Lefort J; Vargaftig BB
    Eur J Pharmacol; 1982 Feb; 78(1):71-9. PubMed ID: 6804248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of platelet-modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition.
    Hanson SR; Harker LA; Bjornsson TD
    J Clin Invest; 1985 May; 75(5):1591-9. PubMed ID: 3923041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolongation of platelet survival in hypercholesterolaemic rabbits by CGS 12970 (3-methyl-2-(3-pyridyl)-1 indoleoctanoic acid) and dazoxiben.
    Butler KD; Butler PA; Shand RA; Ambler J; Wallis RB
    Thromb Res; 1987 Mar; 45(6):751-61. PubMed ID: 3109067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of sulphinpyrazone on human platelet aggregation, 5-hydroxytryptamine release and adhesion ex vivo: comparison with naproxen.
    Nunn B; James FJ
    Br J Clin Pharmacol; 1980 Mar; 9(3):239-45. PubMed ID: 7362733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulphinpyrazone and indomethacin for inhibition of platelet prostaglandin synthesis.
    Huijgens PC; van den Berg CA; Imandt LM; Langenhuijsen MM
    Thromb Res; 1981 Nov; 24(3):267-70. PubMed ID: 7336383
    [No Abstract]   [Full Text] [Related]  

  • 14. Sulphinpyrazone metabolism during long-term therapy.
    Pedersen AK; Jakobsen P
    Br J Clin Pharmacol; 1981 Jun; 11(6):597-603. PubMed ID: 7272176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacology of platelet cyclooxygenase inhibition.
    Patrono C; Ciabattoni G; Patrignani P; Pugliese F; Filabozzi P; Catella F; Davì G; Forni L
    Circulation; 1985 Dec; 72(6):1177-84. PubMed ID: 3933848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of non-steroidal anti-inflammatory drugs on platelet cyclo-oxygenase and lipoxygenase activity.
    Cerletti C
    Int J Tissue React; 1985; 7(4):309-12. PubMed ID: 3934097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of sulfinpyrazone on platelet prostaglandin synthesis and platelet release of serotonin.
    Ali M; McDonald JW
    J Lab Clin Med; 1977 Apr; 89(4):868-75. PubMed ID: 845486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A metabolite of sulphinpyrazone that is largely responsible for the effect of the drug on the platelet prostaglandin pathway.
    Pay GF; Wallis RB; Zelaschi D
    Biochem Soc Trans; 1980 Dec; 8(6):727-8. PubMed ID: 7461266
    [No Abstract]   [Full Text] [Related]  

  • 19. Platelets, cardiac valves and sulphinpyrazone.
    Loeliger EA
    Thromb Haemost; 1982 Apr; 47(2):189. PubMed ID: 7101242
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of indomethacin and sulfinpyrazone on in vivo formation of thromboxane B2 and prostaglandin D2 during arachidonate infusion in rabbits.
    Cerskus AL; Ali M; Zamecnik J; McDonald JW
    Thromb Res; 1978 Mar; 12(3):549-53. PubMed ID: 653641
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.